ETS1 and cancer: Both C228T and C250T mutations generate gain of function ETS1 binding motifs, and the mutant TERT promoter exhibits higher transcriptional activity than does its wild type counterpart in cancer cells, thereby contributing to cancer-specific telomerase activation [5].